J.P. Morgan Reiterates Overweight Rating on Watson Pharmaceuticals

In a report published Monday, J.P. Morgan & Co. reiterated its Overweight rating on Watson Pharmaceuticals (NYSE: WPI ). J.P. Morgan noted, “This morning, Mallinckrodt announced approval of a generic version of Concerta, and it will be the second player in this market along with Watson. Mallinckrodt's approval is very